ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;85:1261-1270. doi:10.1016/j.athoracsur.2007.10.054
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert M. Mentzer, Jr
Claus Bartels
Steven Boyce
Gerald D. Buckberg
Axel Haverich
John Knight
Philippe Menasché
Lars Thulin
Richard D. Weisel
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Mentzer, R. M.
PubMed
Right arrow Articles by Mentzer, R. M., Jr
Related Collections
Right arrow Myocardial protection

Original Articles: Adult Cardiac

Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study

Robert M. Mentzer, Jr, MD*, Claus Bartels, MD, Roberto Bolli, MD, Steven Boyce, MD, Gerald D. Buckberg, MD, Bernard Chaitman, MD, Axel Haverich, MD, John Knight, MD, Philippe Menasché, MD, M. Lee Myers, MD, Jose Nicolau, MD, Maarten Simoons, MD, Lars Thulin, MD, Richard D. Weisel, MD EXPEDITION Study Investigators*

Accepted for publication October 15, 2007.

* Address correspondence to Dr Mentzer, Wayne State University School of Medicine, 540 East Canfield, 1241 Scott Hall, Detroit, MI 48201 (Email: rmentzer{at}med.wayne.edu).

Background: The EXPEDITION study addressed the efficacy and safety of inhibiting the sodium hydrogen exchanger isoform-1 (NHE-1) by cariporide in the prevention of death or myocardial infarction (MI) in patients undergoing coronary artery bypass graft surgery. The premise was that inhibition of NHE-1 limits intracellcular Na accumulation and thereby limits Na/Ca-exchanger–mediated calcium overload to reduce infarct size.

Methods: High-risk coronary artery bypass graft surgery patients (n = 5,761) were randomly allocated to receive either intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours) or placebo. The primary composite endpoint of death or MI was assessed at 5 days, and patients were followed for as long as 6 months.

Results: At 5 days, the incidence of death or MI was reduced from 20.3% in the placebo group to 16.6% in the treatment group (p = 0.0002). Paradoxically, MI alone declined from 18.9% in the placebo group to 14.4% in the treatment group (p = 0.000005), while mortality alone increased from 1.5% in the placebo group to 2.2% with cariporide (p = 0.02). The increase in mortality was associated with an increase in cerebrovascular events. Unlike the salutary effects that were maintained at 6 months, the difference in mortality at 6 months was not significant.

Conclusions: The EXPEDITION study is the first phase III myocardial protection trial in which the primary endpoint was achieved and proof of concept demonstrated. As a result of increased mortality associated with an increase in cerebrovascular events, it is unlikely that cariporide will be used clinically. The findings suggest that sodium hydrogen exchanger isoform-1 inhibition holds promise for a new class of drugs that could significantly reduce myocardial injury associated with ischemia-reperfusion injury.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.